Phosphatidic Acid and mTOR Signaling: How Dietary Lipids Drive Muscle Growth Beyond Protein

June 27, 2026

The lipid most lifters overlook

You track protein to the gram. You time your carbohydrates around training. But when researchers at the University of Tampa gave trained men 750 mg of phosphatidic acid (PA) daily for eight weeks, they gained 2.6 kg of lean body mass compared to 0.1 kg in the placebo group—despite identical protein intakes of 1.6 g/kg (Joy et al., 2014). The effect wasn't from extra calories or better recovery. It came from a direct molecular trigger that sits upstream of everything else your muscles do to grow.

Phosphatidic acid is a glycerophospholipid your body already produces during mechanical tension. When you stretch a loaded muscle, phospholipase D cleaves membrane phosphatidylcholine into PA, which then binds to the FRB domain of mechanistic target of rapamycin complex 1 (mTORC1). This binding stabilizes the complex and amplifies downstream signaling through p70S6K1 and 4E-BP1—the same cascade leucine activates, but through a completely different entry point (Hornberger et al., 2006). The implication is significant: you can enhance mTORC1 activation through dietary lipid composition independently of amino acid availability.

How phosphatidic acid activates mTOR

Understanding the mechanism clarifies why PA works even when protein is already optimized. mTORC1 requires three simultaneous inputs to fully activate: amino acids (especially leucine), growth factors (like insulin and IGF-1), and mechanical signals. Most nutrition strategies target the first two. PA targets the third.

When PA binds mTORC1 at the FRB domain, it competes with the immunosuppressant rapamycin for the same binding site. This competition explains the naming convention—rapamycin inhibits mTOR by occupying the spot PA normally fills (Yoon et al., 2011). Supplemental PA essentially floods that binding site, keeping mTORC1 in its active conformation longer.

The downstream effects cascade through two primary pathways. Phosphorylated p70S6K1 drives ribosomal biogenesis, increasing the cell's capacity to translate mRNA into contractile proteins. Phosphorylated 4E-BP1 releases eIF4E, initiating cap-dependent translation of growth-related transcripts. Both processes require energy, which is why mTORC1 also upregulates glucose uptake and glycolytic enzyme expression (Laplante & Sabatini, 2012).

Critically, PA-mediated mTOR activation appears additive with leucine-mediated activation. Leucine works through the Rag GTPase system to recruit mTORC1 to the lysosomal surface. PA works by stabilizing the complex once it arrives. Combining adequate leucine intake with PA supplementation creates a one-two punch that neither achieves alone (You et al., 2014).

What the human research actually shows

The Joy et al. (2014) study remains the most cited, but it wasn't a fluke. A follow-up investigation using the same 750 mg dose over eight weeks of periodized resistance training found significant increases in squat and bench press strength alongside lean mass gains (Escalante et al., 2016). Subjects were experienced lifters averaging over four years of training—a population notoriously resistant to rapid hypertrophy.

Hoffman et al. (2012) examined PA in resistance-trained men performing a standard four-day split. The PA group showed a 12.7% increase in squat strength versus 9.0% in placebo, with lean body mass increasing 1.7 kg versus 0.2 kg. These weren't untrained subjects experiencing newbie gains; these were men already lifting regularly who added one variable to their existing protocols.

The mechanistic support comes from cell culture and animal work. Phospholipase D1 knockout mice show severely blunted hypertrophy in response to mechanical overload, confirming PA's necessity for growth signaling (You et al., 2014). In C2C12 myotubes, exogenous PA application increases protein synthesis rates by 60-80% within hours, with effects blocked by rapamycin administration (O'Neil et al., 2009).

Dietary sources versus supplementation

Your body synthesizes PA endogenously during training, but dietary intake matters. Soy lecithin contains roughly 30% phosphatidic acid, making it the most concentrated food source. Egg yolks provide approximately 1-2% of their phospholipid content as PA. Cabbage, radishes, and cruciferous vegetables contain small amounts that contribute minimally to total intake (Devane et al., 2000).

The challenge with food-based PA is bioavailability. Digestive phospholipases can hydrolyze PA before absorption, releasing its fatty acid tails and rendering the molecule inactive. Supplemental PA, typically derived from soy and standardized to 50% phosphatidic acid content, uses liposomal or phospholipid complex delivery to survive digestion intact.

Dose-response data suggests 750 mg of actual PA (not raw material weight) represents the effective threshold. Lower doses of 250-375 mg show inconsistent results in trained populations (Andre et al., 2016). The timing appears less critical than with protein—PA's effects operate over hours to days rather than minutes, making it suitable for any point in the day.

Practical applications for different training goals

PA supplementation makes the most sense during dedicated hypertrophy phases when training volume is high and the goal is maximizing contractile protein accretion. During strength phases emphasizing neural adaptations, or during cuts when mTOR suppression is inevitable from caloric restriction, the cost-benefit shifts.

For hybrid athletes balancing endurance and strength, PA presents an interesting option. AMPK activation from aerobic training directly inhibits mTORC1 through TSC2 phosphorylation. PA's ability to stabilize the active mTOR complex may partially buffer against endurance-induced anabolic resistance, though this application lacks direct human trials (Thomson, 2018).

Vegans and vegetarians face particular challenges with phospholipid intake since the richest sources are animal-derived or soy-based. Those avoiding soy can consider sunflower-derived phosphatidic acid supplements, which are now commercially available and show equivalent bioavailability in preliminary testing.

How to apply this

Weekly implementation protocol for a hypertrophy block:

1. Supplementation: Take 750 mg of phosphatidic acid (standardized, soy or sunflower-derived) daily. Split into two doses of 375 mg if gastrointestinal tolerance is a concern. Timing is flexible—morning and post-workout, or with any two meals containing fat for improved absorption.

2. Protein baseline: Maintain protein at 1.6-2.2 g/kg bodyweight. PA enhances mTOR signaling but cannot substitute for amino acid substrate. Ensure at least 3-4 g of leucine per meal to saturate Rag GTPase activation.

3. Training structure: PA benefits are most pronounced with mechanical tension protocols. Prioritize compound movements in the 6-12 rep range with 2-3 second eccentrics. Training volume of 10-20 sets per muscle group weekly provides the stimulus PA amplifies.

4. Dietary fat composition: Include phospholipid-rich foods daily: 2-3 whole eggs, 1 tablespoon soy lecithin granules in shakes, or liberal use of egg-based sauces. These won't replace supplementation but contribute to total PA exposure.

5. Cycle length: Run PA supplementation for 8-12 weeks during accumulation phases. Discontinue during deload weeks and maintenance periods to manage cost and assess baseline response.

6. Monitoring: Track lean mass via DEXA or reliable impedance devices at weeks 0, 4, and 8. Strength improvements on key lifts serve as secondary markers of anabolic response.

Who should prioritize PA supplementation:

- Intermediate to advanced lifters (2+ years training) past rapid newbie adaptations
- Athletes in caloric surplus actively pursuing hypertrophy
- Older lifters (40+) experiencing age-related anabolic resistance
- Those who have optimized protein timing and intake and seek additional ergogenic support

Who can skip it:

- Beginners still making linear progress on basic programming
- Athletes in aggressive caloric deficits where mTOR suppression is intentional
- Those unwilling to commit to 8+ week supplementation cycles

Phosphatidic acid won't replace intelligent programming or adequate protein intake. But for the lifter who has already optimized those variables and wants another lever to pull, the mechanism is clear and the human data is encouraging. A specific dietary lipid, taken consistently, amplifies the molecular signal your training already generates.